Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop

por Coffey MJ, DeCory HH, Lane SS
Publicado 2013

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies

por Fong R, Cavet ME, DeCory HH, Vittitow JL
Publicado 2019

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophtha...

por Blondeau JM, Proskin HM, Sanfilippo CM, DeCory HH
Publicado 2021

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

por Silverstein BE, Morris TW, Gearinger LS, DeCory HH, Comstock TL
Publicado 2012

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility prof...

por Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW
Publicado 2011

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes

por Morris TW, Gearinger LS, Usner DW, Paterno MR, DeCory HH, Comstock TL, Haas W
Publicado 2011

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery

por Bucci FA Jr, Evans RE, Amico LM, Morris TW, Fluet AT, Sanfilippo CM, DeCory HH, Comstock TL
Publicado 2015